Letrovitae Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Letrozole

Indications/Uses

Adjuvant treatment of postmenopausal women w/ hormone receptor +ve invasive early breast cancer. Extended adjuvant treatment of invasive early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 yr. 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Treatment of advanced breast cancer after relapse or progression of the disease in women w/ natural or artificially induced postmenopausal endocrine state, who have been previously treated w/ anti-estrogens.

Dosage/Direction for Use

2.5 mg daily. Adjuvant & extended adjuvant setting Continue for 5 yr or until disease relapse/recurrence, whichever comes first. Advanced or metastatic breast cancer Continue until the progression of the tumor is evident.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Premenopausal endocrine status. Pregnancy & lactation.

MIMS Class

Cancer Hormone Therapy

ATC Classification

L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Letrovitae film-coated tab 2.5 mg

Packing/Price

1's

Letrovitae

letrozole

Manufacturer:

SAG Manufacturing S.L.U.